title: Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases.
abstract: In patients with psoriasis, there is an increased availability of drugs for treatment. However, there are important questions about drug safety for mothers with psoriasis and their fetuses. Currently, there are limited safety data for many of the medications used. In this article, we review current pregnancy risk information for medications commonly used in the treatment of psoriasis. In addition, a list of teratology information resources is included to help practicing clinicians find up-to-date information regarding the safety of the medications they prescribe.
authors.affiliation: Department of Pediatrics, Division of Dermatology, Rady Children's Hospital, University of California, San Diego, California, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Lam
authors.forename: Janine E
authors.initials: JE
authors.lastname: Polifka
authors.forename: Magdalene A
authors.initials: MA
authors.lastname: Dohil
mesh_terms: D017255:Acitretin / Q000009:adverse effects; D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects; D007641:Keratolytic Agents / Q000009:adverse effects*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011358:Product Surveillance, Postmarketing; D011565:Psoriasis / Q000188:drug therapy*; D012871:Skin Diseases / Q000188:drug therapy; D013723:Teratogens / Q000633:toxicity
chemical_list: D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007155:Immunologic Factors; D007641:Keratolytic Agents; D013723:Teratogens; D017255:Acitretin